{
    "clinical_study": {
        "@rank": "114431", 
        "acronym": "RallyX4", 
        "arm_group": {
            "arm_group_label": "Heart failure patients", 
            "description": "Subjects with art failure who receive stable optimal pharmacologic therapy\nModerate to severe heart failure (NYHA Class III-IV) with ejection fraction (EF) \u2264 35% and QRS duration \u2265 120 ms\nLeft bundle branch block (LBBB) with QRS duration \u2265 130 ms, EF \u2264 30%, and mild (NYHA Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I) ischemic heart failure.\nThe study is collecting observational data on regular CRT-D device implants with special focus on the left ventricular ACUITY X4\u00ae Lead Family' ."
        }, 
        "brief_summary": {
            "textblock": "The objective of this study is to collect clinical data on safety and performance of ACUITY\n      X4\u00ae leads when used in a standard clinical setting.\n\n      It is a prospective, non-randomized, observational multicenter study evaluating standard of\n      care.\n\n      For Post Market Clinical Follow up (PMCF) purposes the 3 month implant success rate, adverse\n      events and basic parameters of the lead will be assessed. The cohort of subjects included in\n      this evaluation will be the first 200 subjects which are indicated for PMCF in Rally X4 to\n      receive an ACUITY X4\u00ae lead implant.\n\n      Study endpoints:\n\n      Phrenic Nerve Stimulation (PNS) related CFR through 6 months post-implant (Defined as: rate\n      of freedom from loss of function or operative system revision due to unacceptable PNS\n      threshold) Lead-related Complication-Free Rate (CFR) from Implant through 3 months\n      post-implant."
        }, 
        "brief_title": "Maximizing CRT Delivery by Using MultipolAr Coronary Sinus Lead FamiLy ACUITY\u00ae X4 - RALLY X4 Study", 
        "completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Heartfailure", 
        "condition_browse": {
            "mesh_term": "Heart Failure"
        }, 
        "detailed_description": {
            "textblock": "Clinic visits will occur at:\n\n        -  Enrollment and Consenting Clinic Visit (\u2264 30 days prior to implant procedure)\n\n        -  Implant Procedure (Day 0; all future follow ups based on this date)\n\n        -  Pre-Discharge Clinic Visit (\u2264 7 days post implant procedure) (Required)\n\n        -  One to 6 Month Clinic Visit (20 to 180 days post implant procedure) (Required)\n\n        -  Interim Visit(s) (Any time between the 1 to 6 Month Clinic Visit and Close-out Clinic\n           Visit) (Following study center specific standard of care) (Device follow up optional)\n           AE - reporting required\n\n        -  Close-out Clinic Visit (30 months \u00b1 90 days,  OR 180 days \u00b1 90 days after the study is\n           closed to enrollment, whichever comes first) (Required)\n\n        -  During the trial all AEs, deaths, and changes in the device system must be reported\n\n        -  Devices of subjects who have received a Latitude device will be followed by the Boston\n           Scientific (BSC) Latitude team. Device Data as defined in the Clinical Investigation\n           Plan (CIP), device alerts, and diagnostic data from the standard Latitude database may\n           be collected and entered into the study database at any time."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Subject is willing and capable of providing informed consent\n\n          2. Subject is planned to be implanted with an ACUITY X4\u00ae lead  for left-ventricular\n             pacing and sensing via the coronary venous system in conjunction with a compatible\n             BSC pulse generator\n\n          3. Subject is willing and capable of participating in all visits associated with this\n             study at an approved clinical study center and at the intervals defined by this CIP\n\n          4. Subject is age 18 or above, or of legal age to give informed consent specific to\n             state and national law\n\n        Exclusion Criteria:\n\n          1. Subjects with a hypersensitivity to a maximum single dose of 0.51 mg dexamethasone\n             acetate\n\n          2. Subject is enrolled in any other concurrent study without prior written approval from\n             BSC, with the exception of local mandatory governmental registries and observational\n             studies/registries that are not in conflict and do not affect the following:\n\n               -  Schedule of procedures for the RALLY X4 Study (i.e. should not cause additional\n                  or missed visits);\n\n               -  RALLY X4 Study outcome (i.e. involve medications that could affect the heart\n                  rate of the subject);\n\n               -  Conduct of the RALLY X4 Study per GCP/ ISO 14155:2011/ local regulations as\n                  applicable\n\n          3. Per the implanting physician's discretion, the subject is not a suitable candidate to\n             receive the study device as determined during the implant procedure\n\n          4. Women of childbearing potential who are or might be pregnant at the time of study\n             enrollment or ACUITY X4\u00ae lead implant.\n\n          5. Subject is unwilling or unable to participate in all scheduled study follow up visits\n             at an approved study center\n\n          6. Subject does not anticipate being a resident of the area for the scheduled duration\n             of the trial\n\n          7. Subject's physician does not allow participation\n\n             -"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "The BSC Cardiac Resynchronization Therapy Defibrillators (CRT-Ds) are indicated for\n        subjects with art failure who receive stable optimal pharmacologic therapy (OPT) for heart\n        failure and who meet any one of the following classifications:\n\n          -  Moderate to severe heart failure (New York Heart Association (NYHA) Class III-IV)\n             with ejection fraction (EF) \u2264 35% and QRS duration \u2265 120 ms\n\n          -  Left bundle branch block (LBBB) with QRS duration \u2265 130 ms, EF \u2264 30%, and mild (NYHA\n             Class II) ischemic or non-ischemic heart failure or asymptomatic (NYHA Class I)\n             ischemic heart failure BSCCRT-Ds are also intended to provide ventricular\n             antitachycardia pacing and ventricular defibrillation for automated treatment of\n             life-threatening ventricular arrhythmias."
            }
        }, 
        "enrollment": {
            "#text": "1000", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 7, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02066467", 
            "org_study_id": "Rally X4-10-2013"
        }, 
        "intervention": {
            "arm_group_label": "Heart failure patients", 
            "description": "Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment", 
            "intervention_name": "Left Ventricular lead implant: ACUITY X4\u00ae Lead Family", 
            "intervention_type": "Device", 
            "other_name": [
                "Autogen\u2122X4 CRT-D G179-200 G177-200", 
                "Dynagen\u2122 X4 CRT-D G158-200 G156-200", 
                "Inogen\u2122 X4 CRT-D G148-200 G146-200", 
                "Origen\u2122 X4 CRT-D G058-200 G056-200"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Phrenic Nerve Stimulation", 
            "Heartfailure treatment", 
            "CRT-D therapy", 
            "Quadripolar lead", 
            "Lead related complication free rate"
        ], 
        "lastchanged_date": "February 17, 2014", 
        "location": {
            "contact": {
                "email": "torsten.kayser@bsci.com", 
                "last_name": "Torsten Kayser, Dr.", 
                "phone": "+32-473-877020"
            }, 
            "contact_backup": {
                "email": "Michal.Berlinski@aptivsolutions.com", 
                "last_name": "Michal Berlinski, MD", 
                "phone": "+48 22 594 44 76"
            }, 
            "facility": {
                "address": {
                    "city": "Diegem", 
                    "country": "Belgium", 
                    "zip": "1831"
                }, 
                "name": "Guidant Europe SA / NV a Boston Scientific Company"
            }, 
            "investigator": {
                "last_name": "Haran Burri, Prof", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Belgium"
        }, 
        "number_of_groups": "1", 
        "official_title": "Maximizing CRT Delivery by Using Multipolar Coronary Sinus Lead Family ACUITY\u00ae X4", 
        "other_outcome": {
            "description": "Post Market Clinical Follow-up of the ACUITY X4\u00ae lead will be evaluated in this study.  The outcome of interest will be the 3 month implant success rate. The cohort of subjects included in this evaluation will be the first 200 subjects to receive an ACUITY X4\u00ae lead implant and meet the PMCF eligibility criteria outlined below. The outcomes of interest for the PMCF supplemental analysis will be the percent of subjects successfully implanted with an ACUITY X4\u00ae lead.\nImplant success - is defined as the ability of the ACUITY X4\u00ae lead to be implanted and deliver CRT therapy. Subjects who have multiple lead implant attempts during the procedure, but are eventually successfully implanted with the ACUITY X4\u00ae lead and receive CRT therapy will be classified as a successful implant.", 
            "measure": "3 month Implant success rate for indicated subjects", 
            "safety_issue": "No", 
            "time_frame": "Analysis of first 200 data sets of indicated patients which compleated a 3 month follow up(+/- 30 day) window"
        }, 
        "overall_official": {
            "affiliation": "Guidant Corporation", 
            "last_name": "Torsten Kayser, Dr", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Ethikkommission / Medizinische Fakult\u00e4t/ Otto-von-Guericke-Universit\u00e4t/ Magdeburg", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "February 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "PNS related CFR through 6 months post-implant is greater than the pre-specified performance goal of 94%.\n\u2022 The PNS related CFR will be calculated as the proportion of implanted subjects with no PNS related complications reported through follow-up. The null hypothesis will be rejected and the endpoint considered met if the lower 95% confidence bound for the proportion of subjects with no PNS related complication is greater than 94%.", 
            "measure": "Phrenic Nerve Complication Free Rate", 
            "safety_issue": "No", 
            "time_frame": "median follow up 12 month, a minimum of 6 month and a maximum of 30 month depending of point of enrolment."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02066467"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Lead-related Complication-Free Rate (CFR) from implant through 3 months post-implant is greater than the pre-specified performance goal of 86%.", 
            "measure": "3 month Lead-related Complication-Free Rate (CFR)", 
            "safety_issue": "Yes", 
            "time_frame": "After last patient compleated 1 - 6 month follow up visit window post implant."
        }, 
        "source": "Guidant Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "Aptiv Solutions", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Guidant Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational [Patient Registry]", 
        "target_duration": "12 Months", 
        "verification_date": "February 2014"
    }
}